GLP-1s and Epilepsy Risk

A study in Neurology reports that people with type 2 diabetes taking GLP-1 drugs developed epilepsy less often than those taking a different diabetes drug — a hazard ratio of 0.84, with semaglutide strongest at 0.68.^[1] The journal grades it Class III evidence, and there is a pattern inside the numbers that points away from the neuroprotection explanation.

What was found

Compared with DPP-4 inhibitor users, GLP-1 users had a lower risk of developing epilepsy, and the association held at every follow-up point examined.^[1]

Results held across age and sex subgroups, and a sensitivity analysis excluding patients with overlapping or switching exposure returned a similar figure at 0.71.^[1] The comparator is an active one, which is the design property that separates a credible observational result from a misleading one — the same reason we treated the pneumonia study more seriously than the cancer cohorts.

The pattern that points the other way

Read the follow-up column downward. The association is strongest at one year and weaker at three and five.

A drug that protects neurons should look better with time, not worse. This looks better early.

That shape is hard to reconcile with the neurologic-benefit hypothesis the authors raise. Protection that works through brain physiology would be expected to accumulate over years of exposure. An effect concentrated in the first year fits other explanations more comfortably — differences in who is prescribed a newer drug, in how closely those patients are watched, or in what else was happening around the time of prescribing.

None of that makes the finding wrong. It means the mechanism proposed for it does not match the shape of it, and that is worth noticing before anyone builds a story on top.

Class III evidence, stated by the journal

Neurology formally classifies the strength of evidence in its papers, and this one is graded Class III.^[1] That is the journal itself saying this is observational evidence with recognized limitations, not a demonstration of cause and effect. The authors also name residual confounding as a limitation directly.

What it means practically

• It is not a reason to take a GLP-1. No GLP-1 is approved for anything neurological, and epilepsy is uncommon enough that a relative reduction is a very small absolute one.
• It is mildly reassuring if you have epilepsy and worried a new drug might worsen seizure control. The direction of the data is the opposite.
• It says nothing about seizure control in existing epilepsy — the outcome was developing epilepsy, not managing it.
• It joins a broader pattern of proposed neurologic benefits, one of which has now been tested directly and failed: see the Alzheimer’s trials.

That last point deserves weight. The strongest observational signals in this class have repeatedly not survived randomization. Epilepsy has not been tested, and until it is, this belongs in the interesting column rather than the established one.